for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

キッセイ薬品工業株式会社

4547.T

現在値

2,627.00JPY

変化

-19.00(-0.72%)

出来高

49,400

本日のレンジ

2,620.00

 - 

2,661.00

52週レンジ

2,109.00

 - 

2,692.00

∙ 約20分前の相場を表示しています。

適時開示

Kissei Pharmaceutical says marketing approval for "Beova® Tablets 50mg" for treatment of overactive bladder

Sept 21(Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says Kissei Pharmaceutical Co Ltd and KYORIN Holdings, Inc. <<<4569.T>>> jointly announced today that KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., received approval from the Ministry of Health, Labour and Welfare as of September 21, 2018 to market 'Beova® Tablets 50mg' for the treatment of overactive bladder.

Kissei Pharmaceutical says change of president

April 23 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it appoints Yoshio Furihata as president, to succeed Masaki Morozumi, effective June 27 .

Kissei Pharmaceutical says rating withdrawal by R&I

April 13 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says Rating and Investment Information, Inc. (R&I) withdrew the rating on the company of "A-" -R&I.

Kissei Pharmaceutical completes share repurchase

Feb 13 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it completed repurchase of 1.6 million shares of its common stock, for 4.46 billion yen in total, through ToSTNeT-3, on Feb. 13 .

Kissei Pharmaceutical to repurchase up to 3.7 pct shares and retire treasury shares

Feb 9 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it will repurchase up to 1.8 million shares, representing 3.7 percent of outstanding, for up to 5.02 billion yen, through ToSTNeT-3, on Feb. 13 .Says it will retire 2.5 million shares (4.6 percent of outstanding) of its common stock on March 9 .

JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study

Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it and JCR Pharmaceuticals Co Ltd <<<4552.T>>> jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia .In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin.Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed .

Vifor Pharma: Kissei to market avacopan in Japan

June 9 (Reuters) - VIFOR PHARMA AG <VIFN.S>::KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA.

R&I affirms Kissei Pharmaceutical's rating at "A-" and says stable outlook – R&I

Kissei Pharmaceutical Co Ltd <4547.T>: Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" – R&I .Rating outlook stable– R&I.

Kyorin and KISSEI sign agreement for co-development and co-marketing of KRP-114V

Kyorin Holdings Inc:KYORIN Pharmaceutical Co., Ltd., a wholly-owned subsidiary of KYORIN Holdings, Inc. and Kissei Pharmaceutical Co., Ltd. jointly announced a co-development and co-marketing agreement for an overactive bladder medication of KRP-114V (INN: Vibegron) which is being developed by Kyorin in Japan.

KISSEI PHARMACEUTICAL to retire treasury shares

KISSEI PHARMACEUTICAL CO LTD:To retire 2,600,000 shares (4.57 pct stake) of its common stock on May 15.Says the total shares outstanding will be 54,311,185 shares after the retirement.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up